Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Bronchodilator treatment of stable COPD: long-acting anticholinergics

W. Vincken
European Respiratory Review 2005 14: 23-31; DOI: 10.1183/09058180.05.00009403
W. Vincken
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Hypothetical model of breaking the downward spiral of COPD patients. HRQoL: health-related quality of life.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Inhaled bronchodilators in maintenance treatment of chronic obstructive pulmonary disease; historical evolution along the lines of evidence. Each block represents a class of inhaled bronchodilators or combination of bronchodilators as they became subsequently available on the market. The interconnecting full arrows point to the class with demonstrated superior effects on health outcomes (the evidence being provided by comparative studies referred to by the numbered references between brackets). Dashed interconnecting bi-directional arrows indicate the absence of comparative studies. SABA: short-acting β2-adrenergic receptor agonist; SAAC: short-acting anticholinergic; LAAC: long-acting anticholinergic; LABA: long-acting β2-adrenergic receptor agonist.

Tables

  • Figures
  • TABLE 1—

    Rationale for combining an anticholinergic agent and a β2-adrenergic receptor agonist

    Different mechanisms of action
        Parasympathetic versus sympathetic system
    Different sites of action (?)
        Proximal versus distal airways
    Additive/synergistic effects
    Onset and duration of activity
    Limitation of dose and side-effects
    Improved compliance
    Cost-effectiveness
  • TABLE 2—

    Patient characteristics at screening: 1-yr and 6-month trials with tiotropium

    Casaburi et al. 2002 46Vincken et al. 2002 47Brusasco et al. 2003 50
    TioPboTioIpraTioSalPbo
    Patients n550371356179402405400
    Male %67638486777576
    Age yrs65656465646465
    Duration of COPD yrs8.68.111.411.29.09.99.8
    FEV1 L1.041.001.251.181.121.071.09
    FEV1 % pred39.138.143.941.439.237.738.7
    FEV1/FVC %45.845.545.745.543.742.242.3
    • Data are presented as mean, unless otherwise stated. Tio: tiotropium group; Pbo: placebo group; Ipra: ipratropium group; Sal: salmeterol group; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; FVC: forced expiratory volume.

  • TABLE 3—

    Global initiative for chronic obstructive lung disease objectives of COPD management: does tiotropium meet them?

    Relieve symptomsYes
    Improve exercise toleranceYes
    Improve health statusYes
    Prevent and treat exacerbationsYes
    Prevent and treat complications?
    Reduce mortality? UPLIFT study
    Minimise side effects from treatmentYes
    Prevent disease progression? UPLIFT study
    • ? UPLIFT: awaiting results from the UPLIFT study. COPD: chronic obstructive pulmonary disease.

PreviousNext
Back to top
View this article with LENS
Vol 14 Issue 94 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bronchodilator treatment of stable COPD: long-acting anticholinergics
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Bronchodilator treatment of stable COPD: long-acting anticholinergics
W. Vincken
European Respiratory Review Sep 2005, 14 (94) 23-31; DOI: 10.1183/09058180.05.00009403

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Bronchodilator treatment of stable COPD: long-acting anticholinergics
W. Vincken
European Respiratory Review Sep 2005, 14 (94) 23-31; DOI: 10.1183/09058180.05.00009403
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • RATIONALE FOR THE USE OF ANTICHOLINERGIC AGENTS IN COPD
    • INHALED SHORT-ACTING ANTICHOLINERGICS IN COPD
    • THE COMBINATION OF A SAAC WITH A SABA
    • LONG-ACTING β2-ADRENERGIC RECEPTOR AGONISTS IN COPD
    • COMPARING LABAS TO THE SAAC IPRATROPIUM BROMIDE IN COPD
    • PHARMACOLOGIC PROPERTIES OF THE LONG-ACTING ANTICHOLINERGIC TIOTROPIUM BROMIDE
    • LONG-TERM CLINICAL TRIALS WITH THE LAAC TIOTROPIUM BROMIDE
    • COMPARISON OF THE LAAC TIOTROPIUM BROMIDE TO THE LABA SALMETEROL
    • THE COMBINATION OF A LABA WITH THE LAAC TIOTROPIUM
    • TIOTROPIUM AND PHARMACOLOGICAL VOLUME REDUCTION
    • DOES TIOTROPIUM AFFECT THE NATURAL COURSE OF COPD?
    • CONCLUSION
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Implications and priorities of tobacco control in Belgium and Europe
  • The psychobiology of nicotine dependence
  • Smoking and impact on health
Show more Original Articles

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2022 by the European Respiratory Society